A New Formulation of Intravenous Paracetamol for Fever Management

Launched by UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. · Oct 31, 2014

Keywords

ClinConnect Summary

A new formulation of paracetamol for intravenous administration has been manufactured in Greece by the industry Uni-Pharma (ΑPOTEL Μax®). According to this new formulation, 1g of paracetamol is provided as a flask diluted into 100ml volume with the possibility of immediate connection with the infusion device of the patient. This formulation provides the advantage of a dilution ready-to-use which equals considerable financial benefit; nursing staff is not pre-occupied with the preparation of dilutions and the amount of consumables required for the preparation of this dilution is significantl...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent by the patient
• • 2. Patient of either gender
• • 3. Age equal to or greater than 18 years old
• • 4. Fever onset less than 24 hours
• • 5. Body temperature greater than or equal to 38.50C.
• • 6. Infection of the upper respiratory tract or of the lower respiratory tract or acute pyelonephritis or infection of the skin and soft tissues that can explain fever onset.
• Exclusion Criteria:
• • 1. Age below 18 years old
• • 2. Denial for written consent
• • 3. Intake of paracetamol for any reason either orally or intravenously or intramuscularly the last 12 hours
• • 4. Intake of any non-steroidal anti-inflammatory drug the last 8 hours
• • 5. Intake of any steroidal anti-inflammatory drug the last 12 hours
• • 6. History of liver cirrhosis
• • 7. Serum creatinine greater than 3 mg/dl
• • 8. Aspartate aminotransferase more than 3 times greater than the upper normal limit for the hospital lab
• • 9. Known allergy to non-steroidal anti-inflammatory drugs or to paracetamol
• • 10. Pregnancy or lactation
• • 11. Active bleeding of the upper or the lower gastrointestinal tract
• • 12. Thrombocytopenia defined as any absolute platelet count below 50000/mm3.